Zepastine

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 341390

CAS#: 28810-23-3

Description: Zepastine is a biochemical.


Chemical Structure

img
Zepastine
CAS# 28810-23-3

Theoretical Analysis

MedKoo Cat#: 341390
Name: Zepastine
CAS#: 28810-23-3
Chemical Formula: C22H26N2O3S
Exact Mass: 398.1664
Molecular Weight: 398.521
Elemental Analysis: C, 66.31; H, 6.58; N, 7.03; O, 12.04; S, 8.04

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Zepastine; Zepastina; Zepastinum.

IUPAC/Chemical Name: 6,11-Dihydro-6-methyl-11-(1alphaH,5alphaH-tropan-3alpha-yloxy)dibenzo(c,f)(1,2)thiazepine 5,5-dioxide

InChi Key: DWCWLRAGCYGTNO-JUULQMJNSA-N

InChi Code: InChI=1S/C22H26N2O3S/c1-23-15-11-12-16(23)14-17(13-15)27-22-18-7-3-5-9-20(18)24(2)28(25,26)21-10-6-4-8-19(21)22/h3-10,15-17,22H,11-14H2,1-2H3/t15-,16+,17-,22?

SMILES Code: [H][C@]12C[C@@H](OC(C3=CC=CC=C34)C5=CC=CC=C5N(C)S4(=O)=O)C[C@](CC1)(N2C)[H]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

Preparing Stock Solutions

The following data is based on the product molecular weight 398.521 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Williams G, Blatchford C, Mitchell JP. Evaluation of Nasal Inlet Ports Having Simplified Geometry for the Pharmacopeial Assessment of Mass Fraction of Dose Likely to Penetrate Beyond the Nasopharynx: a Preliminary Investigation. AAPS PharmSciTech. 2018 Sep 17. doi: 10.1208/s12249-018-1179-9. [Epub ahead of print] PubMed PMID: 30225778.

2: El-Masry AA, Hammouda MEA, El-Wasseef DR, El-Ashry SM. Eco-Friendly Green Liquid Chromatographic Determination of Azelastine in the Presence of its Degradation Products: Applications to Degradation Kinetics. J AOAC Int. 2018 Aug 10. doi: 10.5740/jaoacint.17-0472. [Epub ahead of print] PubMed PMID: 30097074.

3: Padmaja D W, Velayutham R, Roy KK. Structure Investigation, Enrichment Analysis and Structure-based Repurposing of FDA-approved Drugs as Inhibitors of BET-BRD4. J Biomol Struct Dyn. 2018 Aug 6:1-22. doi: 10.1080/07391102.2018.1507838. [Epub ahead of print] PubMed PMID: 30079805.

4: Abdelwahab NS, Farid NF, Elagawany M, Abdelmomen EH. Efficient UPLC and CE methods for the simultaneous determination of azelastine hydrochloride and its genotoxic impurity. Biomed Chromatogr. 2018 Jul 25:e4346. doi: 10.1002/bmc.4346. [Epub ahead of print] PubMed PMID: 30045415.

5: Ben-Eli H, Solomon A. Topical antihistamines, mast cell stabilizers, and dual-action agents in ocular allergy: current trends. Curr Opin Allergy Clin Immunol. 2018 Oct;18(5):411-416. doi: 10.1097/ACI.0000000000000473. PubMed PMID: 30020258.

6: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK501061/ PubMed PMID: 30000120.

7: Bachert C, Bousquet J, Hellings P. Rapid onset of action and reduced nasal hyperreactivity: new targets in allergic rhinitis management. Clin Transl Allergy. 2018 Jun 25;8:25. doi: 10.1186/s13601-018-0210-2. eCollection 2018. Review. PubMed PMID: 29983907; PubMed Central PMCID: PMC6016145.

8: Ragab MAA, El-Kimary EI. Investigation of the spectrofluorimetric behavior of azelastine and nepafenac: Determination in ophthalmic dosage forms. Spectrochim Acta A Mol Biomol Spectrosc. 2018 Nov 5;204:260-266. doi: 10.1016/j.saa.2018.06.057. Epub 2018 Jun 15. PubMed PMID: 29936223.

9: Häussler D, Sommer JU, Nastev A, Aderhold C, Wenzel A, Kramer B, Stuck BA, Birk R. Influence of MP 29-02 on ciliary beat frequency in human epithelial cells in vitro. Eur Arch Otorhinolaryngol. 2018 Jun;275(6):1483-1490. doi: 10.1007/s00405-018-4979-3. Epub 2018 Apr 19. PubMed PMID: 29675754.

10: Berger W, Sher E, Gawchik S, Fineman S. Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: A randomized clinical trial. Allergy Asthma Proc. 2018 Mar 1;39(2):110-116. doi: 10.2500/aap.2018.39.4116. PubMed PMID: 29490769; PubMed Central PMCID: PMC5827154.

11: Bousquet J, Meltzer EO, Couroux P, Koltun A, Kopietz F, Munzel U, Kuhl HC, Nguyen DT, Salapatek AM, Price D. Onset of Action of the Fixed Combination Intranasal Azelastine-Fluticasone Propionate in an Allergen Exposure Chamber. J Allergy Clin Immunol Pract. 2018 Sep - Oct;6(5):1726-1732.e6. doi: 10.1016/j.jaip.2018.01.031. Epub 2018 Feb 7. PubMed PMID: 29425904.

12: Haas MJ, Plazarte M, Chamseddin A, Onstead-Haas L, Wong NCW, Plazarte G, Mooradian AD. Inhibition of hepatic apolipoprotein A-I gene expression by histamine. Eur J Pharmacol. 2018 Mar 15;823:49-57. doi: 10.1016/j.ejphar.2018.01.035. Epub 2018 Feb 4. PubMed PMID: 29378195.

13: Tenn MW, Steacy LM, Ng CC, Ellis AK. Onset of action for loratadine tablets for the symptomatic control of seasonal allergic rhinitis in adults challenged with ragweed pollen in the Environmental Exposure Unit: a post hoc analysis of total symptom score. Allergy Asthma Clin Immunol. 2018 Jan 16;14:5. doi: 10.1186/s13223-017-0227-4. eCollection 2018. PubMed PMID: 29371864; PubMed Central PMCID: PMC5771028.

14: Smirnov DS, Kurbacheva OM. [Possibilities of azelastine in the treatment of chronic rhinitis]. Vestn Otorinolaringol. 2017;82(6):52-59. doi: 10.17116/otorino201782652-59. Russian. PubMed PMID: 29260783.

15: Kortekaas Krohn I, Callebaut I, Alpizar YA, Steelant B, Van Gerven L, Skov PS, Kasran A, Talavera K, Wouters MM, Ceuppens JL, Seys SF, Hellings PW. MP29-02 reduces nasal hyperreactivity and nasal mediators in patients with house dust mite-allergic rhinitis. Allergy. 2018 May;73(5):1084-1093. doi: 10.1111/all.13349. Epub 2018 Jan 17. PubMed PMID: 29121401.

16: Steelant B, Seys SF, Van Gerven L, Van Woensel M, Farré R, Wawrzyniak P, Kortekaas Krohn I, Bullens DM, Talavera K, Raap U, Boon L, Akdis CA, Boeckxstaens G, Ceuppens JL, Hellings PW. Histamine and T helper cytokine-driven epithelial barrier dysfunction in allergic rhinitis. J Allergy Clin Immunol. 2018 Mar;141(3):951-963.e8. doi: 10.1016/j.jaci.2017.08.039. Epub 2017 Oct 23. PubMed PMID: 29074456.

17: Karpishchenko SA, Kolesnikova OM. [The effectiveness of the combination of azelastine hydrochloride and mometasone furoate for the intranasal application in the patients presenting with seasonal allergic rhinitis]. Vestn Otorinolaringol. 2017;82(5):44-47. doi: 10.17116/otorino201782544-47. Russian. PubMed PMID: 29072663.

18: Dollner R, Lorentz Larsen P, Dheyauldeen S, Steinsvåg S. A multicenter, prospective, noninterventional study in a Norwegian cohort of patients with moderate-to-severe allergic rhinitis treated with MP-AzeFlu. Allergy Rhinol (Providence). 2017 Oct 1;8(3):148-156. doi: 10.2500/ar.2017.8.0216. PubMed PMID: 29070272; PubMed Central PMCID: PMC5662540.

19: El-Masry AA, Hammouda MEA, El-Wasseef DR, El-Ashry SM. Validated spectroscopic methods for determination of anti-histaminic drug azelastine in pure form: Analytical application for quality control of its pharmaceutical preparations. Spectrochim Acta A Mol Biomol Spectrosc. 2018 Feb 15;191:413-420. doi: 10.1016/j.saa.2017.10.049. Epub 2017 Oct 18. PubMed PMID: 29065333.

20: Doğan R, Aksoy F, Goktas SS, Kocak I, Yıldırım YS, Incir S, Özturan O. Effect of nasal antihistamine on secretory IgA in nasal lavage of rats. Eur Arch Otorhinolaryngol. 2018 Jan;275(1):111-115. doi: 10.1007/s00405-017-4750-1. Epub 2017 Oct 19. PubMed PMID: 29052012.